Physician profile
Michael Lee
NPI 1609370014
$4,075.40
in general payments reported to CMS, 2019-2025
22 companies · $53.78 in 2025
The $53.78 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038 · 2022: $1,392 · 2023: $1,467 · 2024: $125 · 2025: $53.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,047.63 | 2021-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $614.22 | 2022-2023 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $359.57 | 2021-2024 | Dupixent |
| Genzyme Corporation | $299.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $294.73 | 2021-2023 | Cinryze, Takhzyro |
| Grifols USA, LLC | $268.31 | 2022-2023 | Xembify |
| Pharming Healthcare, INC. | $172.29 | 2021-2023 | Ruconest |
| Genentech, INC. | $150.00 | 2022 | |
| Biocryst US Sales Co., LLC | $141.02 | 2021-2022 | |
| Merz North America, INC. | $102.35 | 2023-2024 | Xeomin |
| Abbvie INC. | $100.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.91 | 2021 | |
| Horizon Therapeutics Plc | $81.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $77.00 | 2023 | Proair Digihaler |
| Alk-Abello, INC | $49.70 | 2023 | Odactra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.24 | 2021-2022 | |
| Csl Behring | $43.61 | 2021 | |
| Merck Sharp & Dohme LLC | $38.97 | 2025 | Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.60 | 2021-2022 | |
| Incyte Corporation | $20.44 | 2022 | |
| Kaleo, INC. | $19.05 | 2022 | |
| Revance Therapeutics, INC. | $14.81 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.